Here are 15 updates on GI companies from September:
Pentax Medical obtained a CE Mark for its DEC Duodenoscope.
The FDA approved Pentax's ED34-i10T, a duodenoscope with a disposable, single-use distal cap.
VolitionRx is planning a European launch of its CRC screening product in 2018.
Immuron is making progress on its three clinical trials for IMM-124E, a nonalcoholic steatohepatitis and nonalcoholic fatty liver disease treatment.
IntegraGen's miRpredX 31-3p test was awarded a CE mark for use in the European Union.
The FDA awarded Innovate Biopharmaceuticals' INN-108 orphan drug designation.
CapsoVision launched its CapsoCloud, an exam management system.
Chemistry World reported on Takeda's vision for the future, which involves a move away from generics and the over-the-counter businesses into pharmaceutical research and development.
Takeda CEO Christophe Weber reaffirmed the company's commitment to globalizing its brand and products amid struggling fiscal year 2017 sales.
The National Institute for Health and Care Excellence recommended Allergan's Truberzi for irritable bowel syndrome with diarrhea, making it the first such treatment to be recommended for use by the agency.
Allergan's board of directors authorized the company to buy back $2 billion in stock, while also committing to increasing its quarterly dividends and reaffirming its decision to pay down $3.75 billion in debt by 2018.
Commonwealth Diagnostics relaunched its U.S.-based gastroenterology diagnostic testing business.
The FDA approved Bracco Diagnostics' Tagitol V oral suspension for adult patients undergoing virtual colonoscopy.
A study from England-based Oxford University further validated Medial EarlySign's ColonFlag.
Landos Biopharma completed a series A financing round raising $10 million.